|
MOTOR: Maternal Oral Therapy to Reduce Obstetric Risk
This study is currently recruiting patients
Verified by National Institute of Dental and Craniofacial Research (NIDCR) September 2006
| Sponsored by: |
National Institute of Dental and Craniofacial Research (NIDCR) |
| Information provided by: |
National Institute of Dental and Craniofacial Research (NIDCR) |
| ClinicalTrials.gov Identifier: |
NCT00097656 |
Purpose
The purpose of this study is to determine whether maternal periodontal therapy (tooth cleaning) decreases the rate of preterm deliveries at <37 weeks gestation and to determine the effects of maternal periodontal therapy on the birth weight of infants born less than 37 weeks gestation.
| Condition |
Intervention |
Phase |
Pregnancy Periodontitis Premature Birth |
Procedure: Periodontal Therapy (tooth cleaning) |
Phase III
|
Study Type: Interventional Study Design: Treatment, Randomized, Single Blind, Active Control, Single Group Assignment, Efficacy Study
Official Title: MOTOR: Maternal Oral Therapy to Reduce Obstetric Risk
Further study details as provided by National Institute of Dental and Craniofacial Research (NIDCR):
Primary Outcomes: Birth at less than 37 weeks gestational age
Expected Total Enrollment:
1800
Study start: February 2004;
Expected completion: August 2007 Last follow-up: July 2005;
Data entry closure: May 2007
STUDY DESIGN:
The intervention is designed as a multi-center, randomized, controlled, clinical trial to determine the effects of periodontal
therapy on the rate of preterm birth. Study participants will be assigned to one of two study arms. All pregnant women who
present to the designated Obstetrical (OB) clinics are potential subjects for this study. A total of 1800 patients will be
enrolled at 3 performance sites, enrolling about 600 subjects at each site at a rate of about 171 subjects/year at each site,
randomly assigning these subjects to one of 2 treatment arms. Randomization will be performed using a computer-generated assignment
scheme designed and performed in a masked manner by the data coordinating center. Each performance site will enroll about
300 subjects into each treatment group using the intent-to-treat principle, obtaining follow-up on all subjects. In treatment
Group 1 participants will be assigned to standard localized periodontal therapy of scaling and root planning with subgingival
polishing between three and six months of gestation. Group 2 will receive the same local periodontal therapy immediately following
delivery.
MASKING:
The dental examiner will not be aware of the randomization treatment assignments of participants until after a complete baseline
periodontal examination has been conducted. The study protocol allows the dental examiner to know the treatment assignment
of participants but this knowledge will not affect the assessment of the primary obstetric outcome of the study. OB personnel
or individuals collecting OB data will be masked as to dental treatments. At delivery the second dental exam will be made
without the examiner knowing the pregnancy outcome.
PRIMARY/SECONDARY OUTCOME MEASURES:
The primary outcome is preterm delivery at less than 37 weeks gestational age, as determined by ultrasound dating. Secondary
outcomes include (1) preterm delivery less than 35 weeks, (2) weight for gestational age, and (3) neonatal morbidity/mortality.
It is our central hypothesis that mothers with periodontitis that receive periodontal treatment during the second trimester
of pregnancy will experience a lower rate of preterm delivery at <37 weeks and secondarily <35 weeks; that periodontal treatment
of these pregnant mothers will result in an increase in the weight for gestational age of deliveries occurring less than 37
weeks gestational age and reduce neonatal morbidity and mortality. We will determine the effects of periodontal therapy on
the rate of preterm birth at GA<37 weeks as the principal outcome and on mean birth weight among neonates with GA<35 weeks,
as a secondary outcome adjusting for race, gender and gestational age.
POTENTIAL CONFOUNDERS AND COVARIATES:
There are many potential risk factors that relate to preterm birth and growth restriction that need to be considered in this
investigation. There are also exposures, effect modifiers and covariates that influence periodontal disease status and preterm
birth. Data will be collected on the major variables of interest to include race, age, smoking, previous preterm delivery,
first births, bacterial vaginosis, chorioamnionitis, sexually transmitted diseases (STDs), antibiotic usage, socioeconomic
status (SES) and substance abuse. In addition we will measure fetal fibronectin and collect vaginal smears to examine for
potential subclinical vaginosis. Detailed information will be collected on these potential factors and used to assure that
randomization has effectively balanced risk between treatment arms and to permit post-hoc assessments.
PLAN FOR MONITORING:
There will be an administrative Steering committee consisting of the Obstetric and Periodontal Principal Investigator(PI)
from each clinical site, the NIDCR co-investigators and the Data and Statistical Coordinating Center (DSCC) investigators.
The Steering committee will meet twice the first year and once a year thereafter. Study coordinators will also attend one
of the two annual meetings. Data will be collected on dental, obstetric and neonatal outcomes by the data & statistical coordinating
center, monitoring weekly for adverse events. The DSCC will be collating adverse events and safety data centrally to provide
safety assessment reports to the DSMB. The DSMB will monitor outcomes and adverse events and assure maternal and infant safety
and provide feedback to NIDCR every 6 months or as needed.
ADVERSE EVENTS:
The dental examiner will conduct a comprehensive oral soft tissue (cancer screening) and periodontal examination at baseline
and at post partum. Following enrollment mothers will be followed up by, OB surveillance through parturition, a post-delivery
dental follow-up and neonatal surveillance that includes chart review after discharge. All of these provide an opportunity
to detect and monitor adverse events. All reported and observed serious adverse events will be documented on an adverse event
case report form describing the onset, duration, severity, assessment of causality and relationship to treatment intervention.
This will be followed until resolution. A member of the investigative team will review subject’s OB charts on a weekly basis
to note any adverse events or treatment provided (outside of routine). In addition all neonatal discharge summary findings
will be collected to monitor any adverse neonatal morbidity such as neonatal sepsis and necrotizing enterocolitis. Any dental
treatment will be noted in the subject’s clinical record to be reviewed by the dental examiner.
PLAN FOR DATA ANALYSIS:
The details of the analysis plan appear in the body of the protocol, and are summarized here. The incidence of preterm birth
as the principal outcome will be evaluated using a chi-square test. Approximately 240 cases are expected at gestational age
(GA)<35 weeks. Success of randomization for possible confounders will be evaluated by logistic regression models. Significance
will be indicated by an alpha level of 0.05. Mean birth weight among preterm babies will be analyzed for correlations and
significant differences between study arms using a non-parametric test (Kruskal-Wallis test) Parametric (regression) models
will be used to adjust for gestational age and other factors.]. Analyses will be conducted using the intent to treat philosophy.
Data will be collected on a series of potential risk factors, covariates, confounders and effect modifiers that may influence
the primary and secondary outcomes or periodontal status. Any unbalanced distribution of risks or exposures will be included
in the regression model analysis. Adverse event data will be reported regularly. Interim analyses for efficacy will be conducted
after 600 and 1200 completed pregnancies.
Eligibility
Ages Eligible for Study:
16 Years and above,
Genders Eligible for Study:
Female
Accepts Healthy Volunteers
Criteria
Inclusion Criteria:
- Willing to be randomized and complete treatment protocols and provide informed consent
- Planning on prenatal care and delivery at the enrollment center
- Pregnant and able to complete periodontal treatment prior to 236 weeks gestation
- At least 16 years old at enrollment
- Minimum of 20 teeth present
- Three (3) or more periodontal sites with > 3mm clinical attachment loss
Exclusion Criteria:
- Multiple gestation
- Positive history of HIV infection, AIDS, autoimmune disease, or diabetes (gestational diabetes is acceptable)
- Any medical contraindication to periodontal probing or periodontal treatment that would require antibiotic prophylaxis, (e.g.,
congenital heart disease, use of Phen- fen for weight loss without a clear
Location
and Contact
Information
Please refer to this study by ClinicalTrials.gov identifier
NCT00097656
North CarolinaUniversity of North Carolina, Chapel Hill,,
North Carolina,
27599-7450,
United States; Recruiting
Steven Offenbacher, DDS PhD MMS
919-962-7081
steve_Offenbacher@Dentistry.UNC.EDU
David L. Cochran, DDS, PhD
210-567-3604
cochran@uthscsa.edu
Steven Offenbacher, DDS, PhD,, Principal Investigator Donald J Dudley, MD, Sub-Investigator David L Cochran, DDS, PhD, Sub-Investigator John Hauth, MD, Sub-Investigator Michael S Reddy, DMD, DMS, Sub-Investigator Amy P Murtha, MD, Sub-Investigator
Study chairs or principal investigators
Steven Offenbacher, DDS PhD MMS, Principal Investigator, University of North Carolina
More Information
Study ID Numbers:
NIDCR-14577; 5U01DE014577
Last Updated:
September 14, 2006
Record first received:
November 24, 2004
ClinicalTrials.gov Identifier:
NCT00097656Health Authority: United States: Federal Government ClinicalTrials.gov processed this record on 2006-09-29
|
|